9.75
-0.43(-4.22%)
Currency In USD
Address
21 Ha’arba’a Street
Tel Aviv, 6473921
Israel
Phone
972 3 541 3131
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
53
First IPO Date
January 07, 2013
Name | Title | Pay | Year Born |
Mr. Dror Ben-Asher | Co-Founder, Chairman & Chief Executive Officer | 594,612 | 1966 |
Dr. Reza Fathi Ph.D. | Senior Vice President of Research & Development | 299,291 | 1955 |
Mr. Guy Goldberg J.D. | Chief Business Officer | 338,126 | 1976 |
Mr. Adi Frish | Chief Corporate & Business Development Officer | 339,300 | 1970 |
Mr. Razi Ingber | Chief Financial Officer | 339,819 | 1984 |
Mr. Gilead Raday MPhil, MSc | Chief Operating Officer | 365,556 | 1975 |
Mr. Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. & Director | 469,802 | 1960 |
Ms. Alexandra Okmian | Senior Business Development & Investor Relations Manager | 0 | N/A |
Ms. Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs | 0 | N/A |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.